Item 7.01 Regulation FD Disclosure.

On September 13, 2021, SQZ Biotechnologies Company (the "Company") issued a press release titled "SQZ Biotechnologies Announces First Autoimmune Disease Indication for Tolerizing Antigen Carrier (TAC) Platform." A copy of the press release is attached hereto as Exhibit 99.1.

The Company is also furnishing a corporate presentation, attached as Exhibit 99.2 to this Current Report on Form 8-K, which the Company intends to use from time to time in meetings with investors and others beginning on September 13, 2021. The corporate presentation will also be available in the investor relations section of the Company's website at http://sqzbiotech.com.

The information in this Item 7.01 and Exhibits 99.1 and 99.2 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits



Exhibit
  No.       Description

99.1          Press release issued by SQZ Biotechnologies Company on September 13,
            2021.

99.2          SQZ Biotechnologies Company Corporate Presentation.

104         Cover Page Interactive Data File (embedded with the Inline XBRL
            document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses